Upcoming Events
Priavoid is heading to the Swiss Biotech Day 2026, and we look forward to connecting with peers, life science professionals and potential partners interested in new approaches to address the underlying biology of neurodegenerative diseases, including Alzheimer’s and Parkinson’s Disease.
Our CEO, Philipp Bürling, will be on site on May 4 and 5, 2026, and is available for meetings to discuss our latest clinical and preclinical pipeline data, and how we aim to modify the course of neurodegenerative disorders with our differentiated detangler approach targeting neurotoxic oligomers. If you would like to connect during the conference, please reach out through the partnering platform!
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.